Literature DB >> 23089677

Prognostic factors and outcomes of patients with pulmonary hypertension admitted to the intensive care unit.

Thanh N Huynh1, S Sam Weigt, Catherine A Sugar, Shelley Shapiro, Eric C Kleerup.   

Abstract

PURPOSE: Patients with pulmonary hypertension (PH) can decompensate to the point where they require care in the intensive care unit (ICU). Our objective is to examine the outcomes and characteristics of patients with PH admitted to the ICU.
METHODS: This is a retrospective study of 99 patients with PH who were admitted to the medical ICU of a single tertiary care center. Baseline characteristics, interventions during ICU admission, and ICU and 6-month outcome were documented. Univariate and multivariate logistic regressions were used to evaluate association of patient characteristics with mortality.
RESULTS: Intensive care unit mortality was 30%, and 6-month mortality was 40%. Acute Physiology and Chronic Health Evaluation II score, World Health Organization Group 3 PH, and preexisting treatment with a prostacyclin at time of ICU admission were associated with worse outcome. Patients who received cardiopulmonary resuscitation had 100% mortality. The requirement for mechanical ventilation and dialysis was also associated with increased mortality. Pulmonary artery catheter placement was associated with reduced mortality, specifically if it was placed early during ICU admission and if associated with a change in the present management.
CONCLUSIONS: Mortality is high in critically ill patients with PH. The identification of prognostic baseline characteristics and interventions in the ICU is important and warrants further investigation.
Copyright © 2012 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2012        PMID: 23089677     DOI: 10.1016/j.jcrc.2012.08.006

Source DB:  PubMed          Journal:  J Crit Care        ISSN: 0883-9441            Impact factor:   3.425


  7 in total

1.  Outcomes of cardiopulmonary resuscitation in patients with pulmonary arterial hypertension.

Authors:  Jenny Z Yang; Mazen F Odish; Hannah Mathers; Nicole Pebley; Gabriel Wardi; Demosthenes G Papamatheakis; David S Poch; Nick H Kim; Timothy M Fernandes; Rebecca E Sell
Journal:  Pulm Circ       Date:  2022-04-01       Impact factor: 2.886

2.  Study design and rationale for investigating phosphodiesterase type 5 inhibition for the treatment of pulmonary hypertension due to chronic obstructive lung disease: the TADA-PHiLD (TADAlafil for Pulmonary Hypertension associated with chronic obstructive Lung Disease) trial.

Authors:  Bradley A Maron; Ronald H Goldstein; Sharon I Rounds; Shelley Shapiro; Matthew Jankowich; Eric Garshick; Marilyn L Moy; David Gagnon; Gaurav Choudhary
Journal:  Pulm Circ       Date:  2013-12       Impact factor: 3.017

3.  Inpatient Palliative Care Use in Patients With Pulmonary Arterial Hypertension: Temporal Trends, Predictors, and Outcomes.

Authors:  Vidhu Anand; Saraschandra Vallabhajosyula; Wisit Cheungpasitporn; Robert P Frantz; Hector R Cajigas; Jacob J Strand; Hilary M DuBrock
Journal:  Chest       Date:  2020-08-12       Impact factor: 9.410

Review 4.  Perioperative Evaluation of Patients with Pulmonary Conditions Undergoing Non-Cardiothoracic Surgery.

Authors:  Gilda Diaz-Fuentes; Hafiz Rizwan Talib Hashmi; Sindhaghatta Venkatram
Journal:  Health Serv Insights       Date:  2016-11-09

5.  Pulmonary arterial hypertension in critically ill elderly patients.

Authors:  Yun-Yun Zhang; Fan Xu; Ming Chu; Li-Qing Bi
Journal:  Pak J Med Sci       Date:  2017 Jan-Feb       Impact factor: 1.088

Review 6.  Hospital and intensive care unit management of decompensated pulmonary hypertension and right ventricular failure.

Authors:  Angel Coz Yataco; Melina Aguinaga Meza; Ketan P Buch; Margaret A Disselkamp
Journal:  Heart Fail Rev       Date:  2016-05       Impact factor: 4.214

7.  Critical care outcomes in patients with pre-existing pulmonary hypertension: insights from the ASPIRE registry.

Authors:  Kris Bauchmuller; Robin Condliffe; Jennifer Southern; Catherine Billings; Athanasios Charalampopoulos; Charlie A Elliot; Abdul Hameed; David G Kiely; Ian Sabroe; A A Roger Thompson; Ajay Raithatha; Gary H Mills
Journal:  ERJ Open Res       Date:  2021-04-06
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.